Motley Fool Wealth Management LLC Sells 58,054 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Motley Fool Wealth Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 16.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 297,486 shares of the biopharmaceutical company’s stock after selling 58,054 shares during the period. Motley Fool Wealth Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $6,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Assetmark Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the period. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $39,000. Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in shares of Ultragenyx Pharmaceutical by 26.1% in the third quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 549 shares during the period. 97.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their price target for the company from $61.00 to $25.00 in a research report on Tuesday, March 24th. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. HC Wainwright lowered their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Finally, Barclays lowered their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.56.

Ultragenyx Pharmaceutical Stock Up 5.6%

NASDAQ RARE opened at $22.79 on Wednesday. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -3.73 and a beta of 0.37. The stock’s 50-day simple moving average is $23.79 and its two-hundred day simple moving average is $25.27. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm’s quarterly revenue was down 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.57) EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.57 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director owned 27,951 shares in the company, valued at approximately $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $24.90, for a total value of $116,606.70. Following the completion of the transaction, the chief financial officer owned 110,342 shares in the company, valued at approximately $2,747,515.80. This represents a 4.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 20,103 shares of company stock worth $478,186. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.